Explore 3 Stock Ideas & Industry Insights Download Free Report

Athira Pharma Inc

Company price
None USD 0.00(0%)
Last update at 2026-04-16T21:06:17.138657Z
Market Cap
24.09M

Momentum Score

…

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.41
Low
4.30
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.01
ROE
-84.57%
Net Debt
-89.00M
ROCE
-79.16%
Diluted EPS TTM
-2.84

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -95.64M -54.85M -19.95M -5.16M -5.10M
Net income -87.26M -54.37M -18.63M -4.70M -5.10M
Selling general administrative 32.55M 21.23M 6.71M 1.66M 1.42M
Reconciled depreciation 0.84M 0.48M - - -
Ebit -104.02M -64.02M -20.00M -5.45M -5.01M
Ebitda -78.86M -55.19M -18.67M -4.74M -5.09M
Depreciation and amortization 25.16M 8.84M 1.32M 0.70M -0.08M
Non operating income net other 3.22M 0.33M -1.28M - -
Operating income -104.02M -64.02M -20.00M -5.45M -5.01M
Other operating expenses 88.86M 55.19M 18.67M 4.70M 5.01M
Interest expense 24.32M 0.00M 0.37M 0.35M 0.01M
Interest income - 0.34M 0.12M 0.05M 0.09M
Net interest income - 0.33M -0.24M -0.29M 0.08M
Non recurring -10.00M - - - -
Income tax expense -8.38M -0.48M -1.32M -0.46M -0.08M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 88.86M 55.19M 18.67M 4.70M 5.01M
Total other income expense net 8.38M 9.17M 0.04M 0.29M -0.16M
Net income from continuing ops -100.80M -54.85M -19.95M -5.16M -5.10M
Net income applicable to common shares -95.64M -54.85M -19.99M -5.16M -5.10M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 160.25M 258.15M 332.01M 279.56M 2.19M
Other current assets 5.68M 7.19M 7.04M 7.66M 0.10M
Total liab 30.06M 23.02M 10.92M 5.28M 21.91M
Total stockholder equity 130.19M 235.14M 321.08M 274.28M -19.72M
Other current liab 28.71M 18.60M 8.44M 3.12M 0.85M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -309.21M -191.53M -95.89M -41.04M -21.09M
Other liab - - - - 2.04M
Other assets 0.00M 0.47M 5.27M 84.58M 0.03M
Cash 90.58M 95.97M 110.54M 60.62M 2.06M
Total current liabilities 28.84M 21.43M 9.29M 4.41M 1.27M
Current deferred revenue -0.37M - - - -
Net debt -89.00M -94.06M -108.62M -59.62M -0.50M
Short term debt 0.37M 0.33M 0.29M 0.12M -
Short long term debt total 1.58M 1.91M 1.92M 1.00M 1.55M
Other stockholder equity 439.39M 428.62M 417.36M 35.73M 1.36M
Property plant equipment - 4.05M 3.76M 3.58M -
Total current assets 154.73M 207.53M 260.80M 192.34M 2.16M
Long term investments 0.00M 44.83M 65.94M 83.51M -
Net tangible assets - 235.14M 321.08M 274.28M -19.72M
Short term investments 56.84M 104.38M 143.22M 124.06M 0.00M
Net receivables 1.63M 1.23M 2.34M 1.30M 0.01M
Long term debt - - - - 1.55M
Inventory - -1.23M -2.34M -1.30M -
Accounts payable 0.13M 2.50M 0.57M 1.16M 0.42M
Accumulated other comprehensive income -0.35M -1.96M -0.39M 0.03M -
Common stock total equity - 0.00M 0.00M 0.00M -
Retained earnings total equity - -191.53M -95.89M -41.04M -
Non currrent assets other 0.45M 0.47M 0.06M 0.13M 0.03M
Non current assets total 5.52M 50.62M 71.21M 87.23M 0.03M
Capital lease obligations 1.58M 1.91M 1.92M 1.00M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 58.80M -2.51M -210.07M 1.50M 2.00M
Change to liabilities 2.10M 5.15M 1.10M 0.70M 0.29M
Total cashflows from investing activities 57.66M -4.08M -210.07M 1.51M 2.01M
Net borrowings - - 1.66M 0.87M 1.27M
Total cash from financing activities 0.65M 97.09M 292.75M 0.95M 1.46M
Change to operating activities 8.73M 2.05M 0.06M 0.06M -0.05M
Net income -95.64M -54.85M -19.95M -5.16M -5.10M
Change in cash -14.15M 49.91M 58.57M -1.26M -1.01M
Begin period cash flow 110.54M 60.62M 2.06M 3.32M 4.33M
End period cash flow 96.39M 110.54M 60.62M 2.06M 3.32M
Total cash from operating activities -72.47M -43.10M -24.11M -3.71M -4.48M
Issuance of capital stock 0.00M 96.76M 290.44M 0.00M 0.10M
Depreciation 0.84M 0.48M 0.25M 0.00M 0.00M
Other cashflows from investing activities - - 0.04M 0.01M 0.01M
Change to account receivables 1.11M -1.04M -7.61M -0.02M -0.02M
Sale purchase of stock - 96.76M 208.52M - -
Other cashflows from financing activities 57.66M 0.33M 84.23M 0.95M 1.46M
Change to netincome 10.61M 4.62M 2.00M 0.51M 0.36M
Capital expenditures 1.14M 1.57M 2.32M 2.32M 2.32M
Cash flows other operating 10.04M 1.01M -7.94M - -
Cash and cash equivalents changes -14.15M 49.91M 58.57M - -
Change in working capital 11.94M 6.16M -6.45M 0.68M 0.24M
Stock based compensation 10.61M 4.62M 0.63M 0.25M 0.20M
Other non cash items -0.22M 0.49M 1.65M 0.52M 0.17M
Free cash flow -73.61M -44.67M -26.43M -3.71M -4.48M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S
-1.21
2.90%
40.40 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-6.15
1.14%
531.64 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
4.70
0.49%
957.10 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Athira Pharma Inc

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

18706 North Creek Parkway, Bothell, WA, United States, 98011

425 620 8501

65

Name Title Year Born
Dr. Mark J. Litton M.B.A., MBA, Ph.D. Pres, CEO & Director 1968
Ms. Rachel P. Lenington M.B.A. Chief Operating Officer NA
Mr. Mark F. Worthington J.D. Gen. Counsel & Corp. Sec. NA
Ms. Glenna K. Mileson Chief Financial Officer 1959
Mr. Robert Renninger Director of Accounting & Reporting NA
Ms. Julie Rathbun Head of Investor Relations NA
Dr. Kevin Church Ph.D. Exec. VP of Research 1985
Dr. Mark J. Litton M.B.A., Ph.D. President, CEO & Director 1968
Ms. Rachel P. Lenington M.B.A. Chief Development Officer & COO 1973
Mr. Andrew W. Gengos CFO & Chief Business Officer 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…